BIOAF (Bioasis Technologies) Other Stockholders Equity: $0.00 Mil (As of Nov. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIOAF Bioasis Technologies Inc BIOAF
12 GF Score
Price $0.00
View Full Analysis

What is Bioasis Technologies Other Stockholders Equity?

Bioasis Technologies BIOAF 12 Other Stockholders Equity is $0.00 Mil as of Nov. 2022. GuruFocus rates BIOAF with a GF Score™ of 12/100.

Bioasis Technologies's Other Stockholders Equity for the quarter that ended in Nov. 2022 was $0.00 Mil.

Bioasis Technologies's quarterly Other Stockholders Equity declined from May. 2022 ($-0.00 Mil) to Aug. 2022 ($-0.00 Mil) but then increased from Aug. 2022 ($-0.00 Mil) to Nov. 2022 ($0.00 Mil).

Bioasis Technologies's annual Other Stockholders Equity declined from Feb. 2020 ($0.00 Mil) to Feb. 2021 ($-0.00 Mil) and declined from Feb. 2021 ($-0.00 Mil) to Feb. 2022 ($-0.00 Mil).

Bioasis Technologies Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Bioasis Technologies's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioasis Technologies Other Stockholders Equity Chart

Bioasis Technologies Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.02 0.00 -0.00 -0.00

Bioasis Technologies Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 -0.00 -0.00 0.00
BIOAF
12GF Score
Bioasis Technologies Inc BIOAF
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioasis Technologies Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0.00 Mil mean?
Bioasis Technologies (BIOAF) has a Other Stockholders Equity of $0.00 Mil as of Nov. 2022. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Bioasis Technologies and its competitors.
Is Bioasis Technologies' Other Stockholders Equity too high?
Bioasis Technologies' current Other Stockholders Equity is $0.00 Mil. Overall, Bioasis Technologies has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bioasis Technologies' Other Stockholders Equity compare to VRTX and REGN?
Bioasis Technologies' Other Stockholders Equity of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Bioasis Technologies and its competitors. Bioasis Technologies's current Other Stockholders Equity is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioasis Technologies stock overvalued right now?
Bioasis Technologies (BIOAF) has a current Other Stockholders Equity of $0.00 Mil. The current Other Stockholders Equity is $0.00 Mil. Bioasis Technologies' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Bioasis Technologies (BIOAF), the current Other Stockholders Equity is $0.00 Mil as of Nov. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioasis Technologies Business Description

Address 157 Church Street, 19th Floor, New Haven, CT, USA, 06510
Bioasis Technologies Inc is a development stage biopharmaceutical company engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company's xB3 program describes its proprietary carrier, p97, and components thereof, to deliver therapeutics across the blood-brain barrier (BBB).
12GF Score

Get the complete analysis for BIOAF

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price